查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1801849

HSV 測試市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

HSV Testing Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024年，全球單純皰疹病毒（HSV）檢測市場規模達6.101億美元，預計到2034年將以6.1%的複合年成長率成長，達到11億美元。這一成長動能主要得益於全球單純皰疹病毒感染病例的不斷增加，以及人們對性傳染感染（STI）的認知不斷提高，以及對早期準確診斷的重要性的重視。臨床和家用檢測解決方案的需求不斷成長，持續影響市場動態。多重PCR、自動化血清學平台、快速試劑盒和即時檢測等診斷技術的創新，正在推動檢測準確性和可及性的提高，尤其是在醫療資源匱乏的地區和高通量環境下。

HSV 檢測市場 - IMG1

廣泛的性健康計劃、強化的篩檢政策，以及 HSV 檢測日益融入多疾病譜和電子醫療系統，都有助於提高 HSV 檢測的普及率。以患者為中心、便利診斷的全面轉變，也促使醫療保健產業越來越青睞快速、分散的檢測模式。這些檢測能夠減少污名化，支持更快的臨床決策，並為門診和居家照護環境帶來更多便利，從而增強其在更廣泛的公共衛生策略中的價值。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 6.101億美元
預測值 11億美元
複合年成長率 6.1%

HSV-1/HSV-2 聯合檢測在 2024 年佔據最大佔有率，達到 52.2%，這得益於其能夠在一次檢測中同時檢測兩種類型的單純皰疹病毒。這些涵蓋分子和血清學形式的聯合檢測旨在簡化診斷工作流程，並提高臨床和公共衛生環境中的篩檢準確性。它們能夠識別有症狀和無症狀感染，從而支持做出更明智的醫療決策，尤其是在生殖健康和產前護理領域。隨著高風險族群對高效診斷的需求不斷成長，雙標靶檢測正成為性傳染感染綜合檢測的標準。

2024年，血清學檢測在各類檢測中也佔了最大佔有率，達51.6%。這些基於抗體的檢測在檢測既往HSV感染情況方面備受​​推崇，尤其適用於無明顯症狀的患者。其應用範圍涵蓋大規模篩檢計畫、產前護理和常規性傳染感染診斷。由於血清學檢測相容於高容量實驗室操作，因此能夠實現資料自動輸出、高效的批量檢測，並與集中式診斷系統無縫整合。血清學檢測的可擴展性和成本效益使其成為全球醫院、實驗室和公共衛生計畫的重要工具。

2024年，美國單純皰疹病毒（HSV）檢測市場規模達2.472億美元，鞏固了其在全球單純皰疹病毒檢測領域的重要地位。由於單純皰疹病毒感染在成年人口中普遍存在，對可靠診斷方法的需求仍然強勁。口腔皰疹（通常在兒童早期感染）和生殖器皰疹（一種常見的性傳染感染）都導致了美國檢測量居高不下。完善的醫療基礎設施、積極的疾病宣傳工作以及持續的研究投入，進一步鞏固了美國的市場地位。

引領全球 HSV 檢測市場的知名公司包括雅培實驗室 (Abbott Laboratories)、TRUPCR、Quest Diagnostics、McKesson Medical-Surgical、Bio-Rad Laboratories、賽默飛世爾科技 (Thermo Fisher Scientific)、CTK Biotech、QuidelOrio​​er Corporation、Incoopi​​台、Yumo Fisher Scientic、Pic​​Ya Biotecha​​a、Saku​​Ykia. Bioscience、PrivaPath Diagnostics、F. Hoffmann-La Roche 和 Becton, Dickinson and Company。參與 HSV 檢測市場的公司正透過專注於技術創新、產品組合擴展和全球推廣來提升其地位。一項主要策略包括開發支援分散和早期檢測的快速、即時和組合診斷測試。公司正在投資自動化以及診斷工具與電子健康平台的整合，以提高資料管理和工作流程效率。與醫療保健提供者、公共衛生機構和分銷商的合作有助於擴大覆蓋範圍，尤其是在服務不足的市場。準確性、可負擔性和易用性的不斷改進確保產品滿足日益成長的公共衛生需求。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

  • 產業生態系統分析
  • 產業衝擊力
    • 成長動力
      • HSV感染盛行率上升
      • 分子診斷技術的持續進步
      • 政府對性傳染感染監測和預防計畫的措施和資金
    • 產業陷阱與挑戰
      • 監管和報銷挑戰
      • 社會恥辱和隱私問題
    • 市場機會
      • 持續改進家用和自測試劑盒
  • 成長潛力分析
  • 監管格局
  • 技術進步
    • 當前的技術趨勢
    • 新興技術
  • 供應鏈分析
  • 報銷場景
  • 2024年定價分析
  • 未來市場趨勢
  • 差距分析
  • 波特的分析
  • PESTEL分析

第4章：競爭格局

  • 介紹
  • 公司市佔率分析
    • 北美洲
    • 歐洲
    • 亞太地區
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 關鍵進展
    • 併購
    • 夥伴關係和合作
    • 新產品發布
    • 擴張計劃

第5章：市場估計與預測：按產品，2021 - 2034 年

  • 主要趨勢
  • 儀器
  • 試劑和試劑盒

第6章：市場估計與預測：按類型，2021 - 2034 年

  • 主要趨勢
  • HSV-1/HSV-2 結合
  • 單純皰疹病毒-1
  • 單純皰疹病毒-2

第7章：市場估計與預測：按測試類型，2021 - 2034 年

  • 主要趨勢
  • 血清學檢測
  • 直接檢測試驗
    • 聚合酶連鎖反應
    • 病毒培養
  • 即時檢驗

第8章：市場估計與預測：按樣本類型，2021 - 2034 年

  • 主要趨勢
  • 血
  • 拭子
  • 腦脊髓液
  • 尿

第9章：市場估計與預測：依最終用途，2021 - 2034 年

  • 主要趨勢
  • 醫院
  • 診斷實驗室
  • 居家護理/自我檢測
  • 其他最終用途

第10章：市場估計與預測：按地區，2021 - 2034 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國

第 11 章：公司簡介

  • Abbott Laboratories
  • AdvaCare Pharma
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories
  • bioWORLD
  • CTK Biotech
  • DiaSorin
  • F. Hoffmann-La Roche
  • Hologic
  • Innermost Healthcare
  • McKesson Medical-Surgical
  • Meridian Bioscience
  • PrivaPath Diagnostics
  • Quest Diagnostics
  • QuidelOrtho Corporation
  • Thermo Fisher Scientific
  • TRUPCR
  • ZEUS Scientific
簡介目錄
Product Code: 14582

The Global HSV Testing Market was valued at USD 610.1 million in 2024 and is estimated to grow at a CAGR of 6.1% to reach USD 1.1 billion by 2034. This upward trajectory is largely fueled by the increasing global prevalence of herpes simplex virus infections, along with heightened awareness surrounding sexually transmitted infections (STIs) and the critical importance of early and accurate diagnosis. Rising demand for both clinical and at-home testing solutions continues to shape market dynamics. Innovations in diagnostic technologies-such as multiplex PCR, automated serological platforms, rapid kits, and point-of-care testing-are driving improved accuracy and accessibility, particularly in underserved regions and high-throughput settings.

HSV Testing Market - IMG1

Widespread sexual health initiatives, enhanced screening policies, and the growing integration of HSV testing into multi-disease panels and electronic health systems are contributing to stronger adoption. The overall shift toward patient-centered, accessible diagnostics is also prompting the healthcare sector to increasingly prefer rapid, decentralized testing formats. These tests reduce stigma, support quicker clinical decisions, and offer more convenience in outpatient and home-care environments, reinforcing their value in broader public health strategies.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$610.1 Million
Forecast Value$1.1 Billion
CAGR6.1%

The HSV-1/HSV-2 combined testing segment held the largest share in 2024 at 52.2%, driven by its ability to detect both types of herpes simplex virus in a single test. These combination assays, covering both molecular and serological formats, are designed to streamline diagnostic workflows and enhance screening accuracy across clinical and public health environments. Their capacity to identify both symptomatic and asymptomatic infections supports better-informed medical decisions, particularly in reproductive health and prenatal care contexts. As demand rises for efficient diagnosis in high-risk groups, dual-target assays are becoming standard in comprehensive STI panels.

Serological tests also captured the largest share of 51.6% within the testing type category in 2024. These antibody-based tests are highly valued for detecting prior HSV exposure, especially in patients with no visible symptoms. Their use spans large-scale screening programs, prenatal care, and general STI diagnostics. Thanks to their compatibility with high-volume laboratory operations, serological tests offer automated data output, efficient batch testing, and smooth integration with centralized diagnostics. Their scalability and cost-effectiveness make them essential tools in hospitals, labs, and public health programs worldwide.

United States HSV Testing Market generated USD 247.2 million in 2024, cementing its role as a key contributor to the global HSV testing landscape. With HSV infections widespread across the adult population, the need for reliable diagnostics remains strong. Oral herpes, often contracted early in life, and genital herpes, a common STI, both contribute to high national testing volumes. Supportive healthcare infrastructure, active disease awareness efforts, and continued research investment further strengthen the country's market position.

Notable companies leading the Global HSV Testing Market include Abbott Laboratories, TRUPCR, Quest Diagnostics, McKesson Medical-Surgical, Bio-Rad Laboratories, Thermo Fisher Scientific, CTK Biotech, QuidelOrtho Corporation, Innermost Healthcare, DiaSorin, Hologic, AdvaCare Pharma, ZEUS Scientific, bioWORLD, Meridian Bioscience, PrivaPath Diagnostics, F. Hoffmann-La Roche, and Becton, Dickinson and Company. Companies competing in the HSV testing market are advancing their positions by focusing on technological innovation, portfolio expansion, and global outreach. A major strategy includes the development of rapid, point-of-care, and combination diagnostic tests that support decentralized and early detection. Firms are investing in automation and integration of diagnostic tools with electronic health platforms to improve data management and workflow efficiency. Partnerships with healthcare providers, public health agencies, and distributors help in expanding reach, especially in underserved markets. Continuous improvements in accuracy, affordability, and ease of use ensure that products meet growing public health demands.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/Country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Product trends
    • 2.2.3 Type trends
    • 2.2.4 Test type trends
    • 2.2.5 Sample type trends
    • 2.2.6 End use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of HSV infections
      • 3.2.1.2 Ongoing advancements in molecular diagnostic technologies
      • 3.2.1.3 Government initiatives and funding for STI surveillance and prevention programs
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Regulatory and reimbursement challenges
      • 3.2.2.2 Social stigma and privacy concerns
    • 3.2.3 Market opportunities
      • 3.2.3.1 Ongoing enhancement in home-based and self-testing kits
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
    • 3.4.4 Latin America
    • 3.4.5 Middle East and Africa
  • 3.5 Technological advancements
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Supply chain analysis
  • 3.7 Reimbursement scenario
  • 3.8 Pricing analysis, 2024
  • 3.9 Future market trends
  • 3.10 Gap analysis
  • 3.11 Porter's analysis
  • 3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 North America
    • 4.2.2 Europe
    • 4.2.3 Asia Pacific
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Mergers and acquisitions
    • 4.6.2 Partnerships and collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Instruments
  • 5.3 Reagents and kits

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 HSV-1/HSV-2 Combines
  • 6.3 HSV-1
  • 6.4 HSV-2

Chapter 7 Market Estimates and Forecast, By Test Type, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Serological tests
  • 7.3 Direct detection tests
    • 7.3.1 PCR
    • 7.3.2 Viral culture
  • 7.4 Point-of-care tests

Chapter 8 Market Estimates and Forecast, By Sample Type, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Blood
  • 8.3 Swabs
  • 8.4 Cerebrospinal fluid
  • 8.5 Urine

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 Hospitals
  • 9.3 Diagnostic laboratories
  • 9.4 Home care/self-testing
  • 9.5 Other end use

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 India
    • 10.4.3 Japan
    • 10.4.4 Australia
    • 10.4.5 South Korea
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Argentina
  • 10.6 Middle East and Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 South Africa
    • 10.6.3 UAE

Chapter 11 Company Profiles

  • 11.1 Abbott Laboratories
  • 11.2 AdvaCare Pharma
  • 11.3 Becton, Dickinson and Company
  • 11.4 Bio-Rad Laboratories
  • 11.5 bioWORLD
  • 11.6 CTK Biotech
  • 11.7 DiaSorin
  • 11.8 F. Hoffmann-La Roche
  • 11.9 Hologic
  • 11.10 Innermost Healthcare
  • 11.11 McKesson Medical-Surgical
  • 11.12 Meridian Bioscience
  • 11.13 PrivaPath Diagnostics
  • 11.14 Quest Diagnostics
  • 11.15 QuidelOrtho Corporation
  • 11.16 Thermo Fisher Scientific
  • 11.17 TRUPCR
  • 11.18 ZEUS Scientific